Compare Fox Corp Class B (FOX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Tango Therapeutics Inc. — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.79B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Fox Corp Class B is far larger — about 6.6× Tango Therapeutics Inc.'s market cap, and Fox Corp Class B pays a 1.04% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Tango Therapeutics Inc. for 0 Days on average.
| FOX | TNGX | |
|---|---|---|
Market Cap | $24.79B | $3.74B |
Volume | 707,876 | 3,438,781 |
Sector | Media | Health |
52-Week High | $67.76 | $32.90 |
52-Week Low | $44.39 | $7.50 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.16B | $2.76B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.93, down 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 beating expectations of $1.44, and fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a buy with a price target of $84.75, implying significant upside. A dividend of $0.29 per share is scheduled for payment on September 23, 2026.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected decline in net income margin to 9.83% in 2026 and bearish technical indicators. The stock offers value with a P/E of 14.56 and growth potential, though investors should monitor earnings consistency and market sentiment shifts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
